Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 789-796

  Chen, Yi Bin ^a   Hochberg, Ephraim P ^a   Feng, Yang ^b   Neuberg, Donna ^b   Rawal, Bhupendra ^c   Motyckova, Gabriela ^b   Fisher, David C ^b   McAfee, Steven L ^a   Spitzer, Thomas R ^a   Lacasce, Ann S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Autologous transplant; Lymphoma; R CHOP; Rituximab

Indexed keywords

BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY LARGE CELL LYMPHOMA; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77951778614     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003699852     Document Type: Article

References (18)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
2. Bolwell B, Kalaycio M, Sobecks R, et al. Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma:100 month follow-up. Bone Marrow Transplant 2002;29:673-679.
3. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
4. Popat U, Przepiork D, Champlin R, et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998;16:63-69.
5. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344-2352.
6. Ghesquieres H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006;24:5234-5241.
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
8. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17 (Suppl. 4) : iv31-iv32.
9. Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007; 110 (Suppl. 1) : (Abstract 517).
10. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-1836.
11. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240-2247.
12. Farhat MI, Karmali R, Gregory SA, et al. Incorporating target immunotherapy into standard conditioning regimen prior to autologous stem cell transplantaion (ASCT) improves the transplant outcome for patients with relapsed/refractroy B cell non-Hodgkin lymphoma (B-NHL). Blood 2007; 110 (Suppl. 1) : (Abstract 1911).
13. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. J Clin Oncol 2008;26:3166-3175.
14. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4561-4566.
15. Fenske TS, Hari PN, Carreras J, et al. Impact of pretransplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009;15:1455-1464.
16. Vose JM, Bierman PJ, Lynch JC, et al. Autologous transplant event-free survival (EFS) following failure of CHOP-rituximab (CHOP-R) for diffuse large B-cell lymphoma (DLBCL) is the same as the EFS following failure of CHOP alone. Blood 2004; 104 (Suppl. 1) : (Abstract 890).
17. Adegbola O, Andreadis S, Schuster J, et al. Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2007; 25 (Suppl.) : (Abstract 8122a).
18. Thakkar SG, Sweetenham JW, Rybicki L, et al. Prior therapy with rituximab (R) in patients (pts) with diffuse large B-cell lymphoma (DLBCL) does not affect disease-free (DFS) or overall survival (OS) following high dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 2006; 108 (Suppl. 1) : (Abstract 3054).